NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.

Website: http://neuclone.com

Employees: 12

HQ: +61 2 9209 4020

Location: Sydney, New South Wales, AU

Revenue: $6 million

ConnectPlex.ai is the ideal solution for finding contact information for NeuClone Pty Ltd. We provide company information on millions of companies across the globe, including NeuClone Pty Ltd. Our AI-based B2B lead generation products are designed to help you connect with the right people in NeuClone Pty Ltd. easily find contact details such as email addresses, phone numbers, and more. With ConnectPlex, you can rest assured that you're getting the most accurate and up-to-date information available. Our focus on SEO ensures that our content ranks high in search engines, making it easy for you to find the contact information you need. Whether you're looking to collaborate with NeuClone Pty Ltd. or need to get in touch with their customer service team, ConnectPlex has got you covered. Our keyword-rich content is designed to help you quickly and easily find the contact information you need, saving you time and effort in your search.

NeuClone Pty Ltd is a clinical stage biopharmaceutical company located in Sydney, Australia. The company is focused on developing and commercializing high-quality biosimilar products, with a deep pipeline of products in various stages of development. NeuClone's mission is to create affordable and accessible biologics that meet the demands of both new and established markets globally. Led by a team of industry veterans, NeuClone is differentiated by its unmatched pipeline and its unique approach to biosimilar development, known as the "Right From the Start" approach. This approach involves continually confirming biosimilarity at the earliest stages and throughout development, ensuring that the company's products are of the highest quality and meet regulatory standards. NeuClone's product pipeline includes a range of therapeutic antibodies and biosimilars, including monoclonal antibodies developed in CHO cells. The company's focus on biosimilar antibody development in CHO cells is a testament to its commitment to innovation and cutting-edge technology. With a strong management team and a solid track record of success, NeuClone is poised to make a significant impact in the biopharmaceutical industry. The company's dedication to creating affordable and accessible biologics has the potential to improve the lives of millions of people around the world.

NeuClone is a company that creates and sells copies of expensive medicines called biosimilars. They have a team of experienced professionals who are focused on making a wide range of high-quality biosimilars that are affordable and meet the demand in different markets around the world. NeuClone stands out from other companies because they have a strong pipeline of biosimilars in development and they make sure that their products are similar to the original medicines at every stage of development. They call this approach "Right From the Start®".